rosiglitazone has been researched along with Bone Fractures in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (62.07) | 29.6817 |
| 2010's | 10 (34.48) | 24.3611 |
| 2020's | 1 (3.45) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, D; Guo, J; Mo, C; Qin, J; Shen, L; Sun, Y; Wei, H; Xiong, Y; Yue, R; Zhang, X; Zhang, Y; Zhao, C | 1 |
| Fitzpatrick, LA; Guldberg, RE; Hoffman, SJ; Jolette, J; Kumar, S; Mansell, P; Samadfam, R; Smith, SY | 1 |
| Brito, JP; Gionfriddo, MR; Leppin, AL; Montori, VM; Morey-Vargas, OL; Murad, MH | 1 |
| Curtis, PS; Home, PD; Jones, NP | 1 |
| Ambrosius, WT; Banerji, MA; Bauer, DC; Bonds, DE; Chen, H; Cohen, RM; Hamilton, BP; Isakova, T; Josse, RG; Margolis, KL; Schnall, AM; Schwartz, AV; Sellmeyer, DE; Shibli-Rahhal, A; Simmons, DL; Sood, A; Vittinghoff, E; Williamson, JD | 1 |
| Bilezikian, JP; Bogado, CC; Cobitz, AR; Fitzpatrick, LA; Lewiecki, EM; Miller, CG; Nino, AJ; Northcutt, AR; Paul, G; Wooddell, MJ; Yu, HJ | 1 |
| Kenny, C | 1 |
| Loke, YK; Singh, S | 1 |
| Lipscombe, LL | 1 |
| Furberg, CD; Loke, YK; Singh, S | 1 |
| Anastasilakis, AD; Goulis, DG; Toulis, KA | 1 |
| Sinclair, A; Viljoen, A | 1 |
| Beck-Nielsen, H; Curtis, PS; Gomis, R; Hanefeld, M; Home, PD; Jones, NP; Komajda, M; McMurray, JJ; Pocock, SJ | 1 |
| Hamada, Y | 1 |
| Douglas, IJ; Evans, SJ; Pocock, S; Smeeth, L | 1 |
| Dixit, A; Pandey, P | 1 |
| Eliasson, B; Gustafson, B; Smith, U | 1 |
| Curcin, V; Elliott, P; Hughes, RI; Khunti, K; Little, MP; Majeed, A; Millett, CJ; Molokhia, M; Ng, A; Tzoulaki, I; Wilkins, MR | 1 |
| Aubert, RE; Chen, W; Haffner, SM; Herrera, V; Pendergrass, M | 1 |
| Asao, K; Bilik, D; Brown, MB; Crosson, JC; Duru, OK; Ferrara, A; Herman, WH; Hsiao, VC; Karter, AJ; Kim, C; Lee, PG; Marrero, DG; McEwen, LN; Pomeroy, NE; Selby, JV; Subramanian, U | 1 |
| Francucci, CM; Marcocci, C; Viccica, G | 1 |
| Biagi, C; Marchesini, G; Marra, A; Motola, D; Piccinni, C; Poluzzi, E; Raschi, E | 1 |
| Bryant, B; Jain, SK; Yaturu, S | 1 |
| Hampton, T | 1 |
| Schwartz, AV; Sellmeyer, DE | 1 |
| Henry, MJ; Nicholson, GC; Pasco, JA | 1 |
| Eckert, S; Erdmann, E; Forst, T; Lundershausen, R; Scherbaum, WA; Schnell, O; Schumm-Draeger, PM; Standl, E; Tschöpe, D; Walter, H; Weber, M | 1 |
| Aftring, RP; Haffner, SM; Heise, MA; Herman, WH; Holman, RR; Kahn, SE; Kravitz, BG; Lachin, JM; Viberti, G; Yu, D; Zinman, B | 1 |
| Grey, AB | 1 |
7 review(s) available for rosiglitazone and Bone Fractures
| Article | Year |
|---|---|
Systematic reviews to ascertain the safety of diabetes medications.
Topics: Acidosis, Lactic; Blood Glucose; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Female; Fractures, Bone; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Male; Meta-Analysis as Topic; Metformin; Oxazoles; Pancreatic Neoplasms; Risk Assessment; Rosiglitazone; Thiazolidinediones; Urinary Bladder Neoplasms | 2014 |
Rosiglitazone and the thiazolidinediones: a changing context.
Topics: Fractures, Bone; Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
The safety of rosiglitazone in the treatment of type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fractures, Bone; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Infarction; Risk Factors; Rosiglitazone; Thiazolidinediones | 2008 |
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.
Topics: Bone Density; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Male; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2009 |
Safety and efficacy of rosiglitazone in the elderly diabetic patient.
Topics: Age Factors; Aged; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Fractures, Bone; Heart Failure; Humans; Hypoglycemic Agents; Myocardial Ischemia; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2009 |
[Relationship between insulin resistance and bone metabolism].
Topics: Adipokines; Animals; Bone and Bones; Carbohydrate Metabolism; Fractures, Bone; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2009 |
The role of PPARγ for the osteoblastic differentiation.
Topics: Adipocytes; Animals; Cell Differentiation; Female; Fractures, Bone; Humans; Mesenchymal Stem Cells; Mice; Osteoblasts; PPAR gamma; Rats; Rosiglitazone; Thiazolidinediones | 2010 |
5 trial(s) available for rosiglitazone and Bone Fractures
| Article | Year |
|---|---|
Cancer and bone fractures in observational follow-up of the RECORD study.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Fractures, Bone; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Neoplasms; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2015 |
Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Fractures, Bone; Humans; Hypoglycemic Agents; Incidence; Longitudinal Studies; Male; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2015 |
Evaluation of Quantitative Computed Tomography Cortical Hip Quadrant in a Clinical Trial With Rosiglitazone: A Potential New Study Endpoint.
Topics: Cortical Bone; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Femur Neck; Fractures, Bone; Humans; Hypoglycemic Agents; Longitudinal Studies; Postmenopause; Risk Factors; Rosiglitazone; Thiazolidinediones; Tomography, X-Ray Computed | 2016 |
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.
Topics: Administration, Oral; Angina, Unstable; Body Weight; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diuretics; Drug Therapy, Combination; Drug Utilization; Female; Fractures, Bone; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Neoplasms; Prospective Studies; Rosiglitazone; Sex Factors; Stroke; Sulfonylurea Compounds; Thiazolidinediones | 2009 |
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
Topics: Age of Onset; Aged; Diabetes Mellitus, Type 2; Disease Progression; Female; Fractures, Bone; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2008 |
17 other study(ies) available for rosiglitazone and Bone Fractures
| Article | Year |
|---|---|
Single-cell transcriptomics of LepR-positive skeletal cells reveals heterogeneous stress-dependent stem and progenitor pools.
Topics: Aging; Animals; Antigens, Ly; Bone and Bones; Cell Differentiation; Cell Lineage; Colony-Forming Units Assay; Female; Fractures, Bone; Gene Expression Profiling; Homeodomain Proteins; Male; Membrane Proteins; Mice, Inbred C57BL; Mice, Transgenic; Receptors, Leptin; Rosiglitazone; Single-Cell Analysis; Stem Cells; Stress, Physiological | 2022 |
The effect of rosiglitazone on bone mass and fragility is reversible and can be attenuated with alendronate.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Time Factors; X-Ray Microtomography | 2013 |
Thiazolidinediones: do harms outweigh benefits?
Topics: Bone Density; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Male; Pioglitazone; Risk Assessment; Risk Factors; Rosiglitazone; Sex Factors; Thiazolidinediones; Treatment Outcome | 2009 |
Thiazolidinedione use and the risk of fractures.
Topics: Bone Density; Case-Control Studies; Confidence Intervals; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Fractures, Bone; Greece; Humans; Hypoglycemic Agents; Incidence; Male; Odds Ratio; Pioglitazone; Reference Values; Risk Assessment; Rosiglitazone; Thiazolidinediones | 2009 |
The risk of fractures associated with thiazolidinediones: a self-controlled case-series study.
Topics: Aged; Bone and Bones; Case-Control Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones; United Kingdom | 2009 |
Rosiglitazone and pioglitazone. Beware fractures.
Topics: Diabetes Mellitus, Type 2; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Male; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2009 |
Thiazolidinediones increase the wingless-type MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: a link with osteogenesis.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Bone Density; Diabetes Mellitus, Type 2; Fractures, Bone; Gene Expression Regulation; Humans; Hypoglycemic Agents; Intercellular Signaling Peptides and Proteins; Mice; Osteogenesis; PPAR gamma; Rosiglitazone; Signal Transduction; Thiazolidinediones; Wnt Proteins | 2010 |
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bone; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2009 |
Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Pioglitazone; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2010 |
Thiazolidinediones and fractures: evidence from translating research into action for diabetes.
Topics: Adult; Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones; Translational Research, Biomedical | 2010 |
Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database.
Topics: Adverse Drug Reaction Reporting Systems; Bone and Bones; Cardiovascular System; Clinical Trials as Topic; Databases, Factual; Eye; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Macular Edema; Male; Meta-Analysis as Topic; Myocardial Infarction; Odds Ratio; Pioglitazone; Risk; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2012 |
Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men.
Topics: Bone Density; Bone Resorption; Diabetes Mellitus, Type 2; Fractures, Bone; Humans; Hypoglycemic Agents; Male; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Diabetes drugs tied to fractures in women.
Topics: Chromans; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones; Troglitazone | 2007 |
Thiazolidinedione therapy gets complicated: is bone loss the price of improved insulin resistance?
Topics: Bone Density; Bone Resorption; Diabetes Mellitus, Type 2; Fractures, Bone; Humans; Hypoglycemic Agents; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Weight gain may contribute to increased fracture risk in women treated with rosiglitazone.
Topics: Animals; Diabetes Complications; Female; Fractures, Bone; Humans; Mice; Middle Aged; Obesity; Rats; Rosiglitazone; Thiazolidinediones | 2007 |
[Determining the current position regarding the value of pioglitazone for the therapy of diabetes].
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fractures, Bone; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Osteoporosis, Postmenopausal; Pioglitazone; PPAR gamma; Risk Assessment; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Skeletal toxicity of thiazolidinediones.
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Risk Factors; Rosiglitazone; Thiazolidinediones | 2008 |